Palatin Technologies Inc. (PTN)

Trade PTN now with
1/19/2023 7:31:31 AM Palatin Initiates Enrollment In Phase 2 Bremelanotide BREAKOUT Study In Patients With Diabetic Kidney Disease
1/10/2023 7:44:04 AM Frontiers In Immunology Publishes Pre-Clinical Study Of Palatin's PL8177 Demonstrating Therapeutic Effects
1/5/2023 7:34:35 AM Palatin Q2 Net Product Revenue $1.0 Mln, Up 15.4% Over Prior Quarter
11/14/2022 7:33:41 AM Palatin Technologies Q1 Net Loss $8.3 Mln Or $0.86/shr Vs Net Loss $7.1 Mln Or $0.75/shr Prior Year
10/20/2022 7:32:36 AM Palatin Technologies Enolls First Patient In Phase 2 Study Of PL8177 In Ulcerative Colitis
10/13/2022 7:32:54 AM Palatin Technologies Q1 Net Product Revenue For Prescriptions Dispensed Up 20% To $856K Over Prior Quarter
9/22/2022 7:32:03 AM Palatin Q4 Net Loss $12.8 Mln Or $1.34/shr Vs Net Loss $13.9 Mln Or $1.47/shr Prior Year
9/8/2022 7:32:01 AM Palatin Initiates Patient Recruitment For Phase 2 Study Of Oral PL8177 For Treatment Of Ulcerative Colitis
8/19/2022 7:32:30 AM Palatin Intents To Effect 1-for-25 Reverse Stock Split On August 30
8/16/2022 7:31:33 AM Palatin Reports Positive Interim Analysis In Phase 3 Study Of PL9643 In Patients With Dry Eye Disease
7/26/2022 7:32:14 AM Palatin Technologies Q4 Net Product Revenue Up 225% Over Prior Quarter
5/17/2022 7:32:38 AM Palatin Technologies Q3 Net Loss $7.6 Mln Or $0.03/shr Vs Loss Of $5.7 Mln Or $0.02/shr Prior Year